Transplantation Reports最新文献

{"title":"Association between pre-transplant body mass index and post-transplant infection and rejection in liver transplant recipients: A single-center retrospective cohort study","authors":"Mohsen Aliakbarian ,&nbsp;Saeed Sharafi ,&nbsp;Hossein Bahari ,&nbsp;Armin Doostparast ,&nbsp;Reza Nejad Shahrokh Abadi ,&nbsp;Mahboobeh Ghasemzadeh Rahbardar ,&nbsp;Rozita Khodashahi","doi":"10.1016/j.tpr.2026.100201","DOIUrl":"10.1016/j.tpr.2026.100201","url":null,"abstract":"<div><h3>Background</h3><div>The relationship between pre-transplant body mass index (BMI) and post-transplant outcomes remains a topic of interest in liver transplantation. This study aimed to investigate the association between pre-transplant BMI categories and the incidence of infections and graft rejection among liver transplant recipients.</div></div><div><h3>Methods</h3><div>The data for this study were obtained from a single-center LT database, consisting of 479 patients with ages &gt;18 who underwent their first liver transplant during the period from May 2013 to September 2022. The patients were categorized into four groups based on their pre-transplant BMI: underweight (BMI &lt; 18.5 kg/m²), normal weight (BMI from 18.5 to 24.9 kg/m²), overweight (BMI from 25 to 29.9 kg/m²), and obese (BMI ≥ 30 kg/m²).</div></div><div><h3>Results</h3><div>Out of the total 479 patients included in the study, 13.4% and 11.7% experienced infectious complications and graft rejection following their liver transplant, respectively. Obesity was observed in 18.2% of patients and 6.5% were classified as underweight. Although the underweight group exhibited the highest rates of complications, no statistically significant differences were found among the BMI categories (P = 0.152 for infections; P = 0.072 for graft rejection), even after adjusting for confounders such as age and sex.</div></div><div><h3>Conclusions</h3><div><u>In this study, pre-transplant BMI was not an independent predictor of post-transplant infections or graft rejection</u>. While the underweight group displayed higher rates of infections and graft rejection, these differences were not statistically significant. Further research is needed to explore the complex mechanisms underlying these associations and to identify additional factors influencing post-transplant success.</div></div>","PeriodicalId":37786,"journal":{"name":"Transplantation Reports","volume":"11 2","pages":"Article 100201"},"PeriodicalIF":0.0,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146175508","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessing the specificity of the virtual cross-match in kidney transplant patients: A quality improvement initiative in a Canadian institution","authors":"Martin Igbokwe ,&nbsp;Archit Jain ,&nbsp;David Beaune ,&nbsp;Atheer Alqahtani ,&nbsp;Abdullah Alfaifi ,&nbsp;Lakshman Gunaratnam ,&nbsp;Alp Sener ,&nbsp;Patrick Luke ,&nbsp;Abubaker Sidahmed","doi":"10.1016/j.tpr.2026.100200","DOIUrl":"10.1016/j.tpr.2026.100200","url":null,"abstract":"<div><h3>Background</h3><div>The virtual crossmatch (VXM) is a novel tool used to identify donor-specific antibodies (DSA) in kidney transplantation without requiring physical donor samples, reducing cold ischemia time (CIT). This study evaluates the specificity of VXM compared to the prospective crossmatch (PXM)/flow cytometric crossmatch (FCXM) in kidney transplant recipients with varying levels of cumulative panel reactive antibodies (cPRA) at a Canadian tertiary care institution.</div></div><div><h3>Methods</h3><div>We conducted a retrospective analysis of all VXMs performed at the London Health Sciences Centre, Ontario from 2020 to 2023. Data included patient demographics, cPRA levels, FCXM results, and DSA titers. Patients were categorized by cPRA levels (0–20, 21–40, 41–60, 61–80, and 81–100%), and the Z-test was used to compare the proportion of positive crossmatches across these groups. A p-value of &lt;0.05 was considered statistically significant.</div></div><div><h3>Results</h3><div>Of 955 patients reviewed, 62% had a cPRA ≤20%. Positive PXM rates were not significantly different in the cPRA 0–20, 21–40, and 41–60% groups (<em>p</em> &gt; 0.05). However, significantly higher positive PXM rates were observed in the 61–80% and 81–100% groups (<em>p</em> = 0.0001 and <em>p</em> = 0.00013, respectively). Positive DSA titers were statistically significant only in the cPRA 81–100% group (24%, <em>p</em> = 0.0002). VXM demonstrated high specificity for predicting negative PXM outcomes in cPRA ≤60% but was less predictive for highly sensitized patients (cPRA &gt;60%).</div></div><div><h3>Conclusions</h3><div>The VXM reliably predicts negative FCXM outcomes in patients with cPRA ≤60%, supporting its use in this population to streamline workflows and reduce CIT. For cPRA &gt;60%, confirmatory FCXM remains necessary prior to transplantation due to the persistent likelihood of positive crossmatches, likely driven by non-HLA antibodies and allele-specific DSAs. Tailored protocols and technological advancements are essential to optimize crossmatch processes.</div></div>","PeriodicalId":37786,"journal":{"name":"Transplantation Reports","volume":"11 2","pages":"Article 100200"},"PeriodicalIF":0.0,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146175510","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Liver transplantation in unresectable colorectal liver metastases–Defining the optimal candidate","authors":"Visnuka Sivasubramaniam ,&nbsp;Richard Xavier Sousa Da Silva ,&nbsp;Christoph Eckharter ,&nbsp;Yi-Ping Sng ,&nbsp;Ralph Fritsch ,&nbsp;Andreas E. Kremer ,&nbsp;Pascale Tinguely ,&nbsp;Jose Oberholzer ,&nbsp;Henrik Petrowsky","doi":"10.1016/j.tpr.2026.100196","DOIUrl":"10.1016/j.tpr.2026.100196","url":null,"abstract":"<div><div>Approximately half of all patients with colorectal cancer develop liver metastases over the course of their disease. While 20–30 % of patients with colorectal liver metastases (CRLM) are potential candidates for curative hepatic resection, those with unresectable CRLM (uCRLM) have historically been limited to systemic chemotherapy or best supportive care. Recent evidence from the randomized controlled TransMet trial has demonstrated that orthotopic liver transplantation in carefully selected patients with uCRLM results in an 8-fold higher 5-year survival compared with chemotherapy only (73 % versus 9 %). When patient selection is further refined using tumor biology characteristics and response to chemotherapy as key selection criteria, encouraging 5-year survival rates ranging from 50–83 % after LT have been reported. Although post-transplant tumor recurrence remains a major clinical concern, recurrent disease most commonly manifests as pulmonary metastases, which are frequently amenable to effective local or systemic treatment. Growing clinical evidence indicates that LT for uCRLM is emerging as a viable therapeutic strategy for highly selected patients lacking otherwise curative options. Nevertheless, the field urgently requires standardized selection protocols and clear guidance on how such transplant candidates should be prioritized within national organ allocation systems.</div></div>","PeriodicalId":37786,"journal":{"name":"Transplantation Reports","volume":"11 2","pages":"Article 100196"},"PeriodicalIF":0.0,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146154173","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Inspiratory muscle training in solid organ transplant candidates and recipients: A scoping review","authors":"Delila Farias ,&nbsp;Ivan Daniel B. Nogueira ,&nbsp;Gabriel Faucher ,&nbsp;Feng Jiang ,&nbsp;Daniel Coughlan ,&nbsp;Patrícia Angélica de M.S. Nogueira ,&nbsp;Nicholas Bourgeois ,&nbsp;Dmitry Rozenberg ,&nbsp;Jill Boruff ,&nbsp;Tania Janaudis-Ferreira","doi":"10.1016/j.tpr.2026.100198","DOIUrl":"10.1016/j.tpr.2026.100198","url":null,"abstract":"<div><h3>Background</h3><div>Solid organ transplants (SOT) such as those of the lungs, heart, kidneys, pancreas, and liver are associated with physical impairments and functional limitations. Rehabilitation is a key component of care both pre- and post-surgery. Inspiratory muscle training (IMT) can be used to strengthen the respiratory muscles and may have significant effects on clinical outcomes and healthcare utilization in SOT candidates and recipients.</div></div><div><h3>Objectives</h3><div>This scoping review aims to determine how IMT is used in SOT candidates and recipients by: 1) identifying which populations have been considered for IMT, 2) describing the IMT protocols used, and 3) examining the impact of IMT on clinical outcomes and healthcare utilization.</div></div><div><h3>Methods</h3><div>A scoping review was conducted following the framework outlined by Arksey &amp; O'Malley. A comprehensive search was performed in MEDLINE, EMBASE, and CINAHL. Articles were screened based on inclusion and exclusion criteria by two investigators. Data were extracted and reported to address the research objectives.</div></div><div><h3>Results</h3><div>Fourteen studies targeting heart, lung, liver, kidney, and heart-lung transplant candidates or recipients evaluated IMT using different intensity, duration, and devices. Most studies focused on heart and lung transplant. Outcomes such as inspiratory muscle pressure, dyspnea, exercise capacity, and quality of life were assessed. IMT demonstrated improvements in respiratory strength, symptoms, and physical function across organ groups.</div></div><div><h3>Conclusion</h3><div>IMT shows promise in improving clinical outcomes for SOT candidates and recipients. However, variability in protocols highlights the need for further research to define optimal strategies and assess long-term impacts on healthcare utilization.</div></div>","PeriodicalId":37786,"journal":{"name":"Transplantation Reports","volume":"11 2","pages":"Article 100198"},"PeriodicalIF":0.0,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146175509","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analysis of outcomes following change in granulocyte colony-stimulating factor administration policy in multiple myeloma patients receiving melphalan autologous bone marrow transplant","authors":"Maranda Renouard ,&nbsp;Julie Asch ,&nbsp;Jacob Wilkes ,&nbsp;Daanish Hoda ,&nbsp;Prashant Sharma ,&nbsp;Riki Ashment ,&nbsp;Ryan Jensen ,&nbsp;Bradley Hunter","doi":"10.1016/j.tpr.2026.100199","DOIUrl":"10.1016/j.tpr.2026.100199","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Background&lt;/h3&gt;&lt;div&gt;Engraftment is a determining factor for hospital discharge following autologous hematopoietic stem cell transplant (auto-HSCT). Delays in engraftment can lead to a longer hospital length of stay (LOS), infection, and higher financial costs. In an effort to decrease the time to engraftment, Intermountain Health’s Blood and Marrow Transplant Program modified the start time of granulocyte colony-stimulating factor (GCSF) initiation from Day +6 to Day +1.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Objective&lt;/h3&gt;&lt;div&gt;This study is a post-implementation retrospective review to determine if this practice change affects engraftment, hospital LOS, engraftment syndrome (ES) occurrence, and overall survival (OS).&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Study Design&lt;/h3&gt;&lt;div&gt;The review was conducted among multiple myeloma and plasma cell disorder patients 18 years or older who received melphalan-based auto-HSCT at LDS Hospital. Comparison groups are those that received G-CSF on Day +6 after transplant (control) compared to Day +1 (intervention). Data was obtained via chart review and from preexisting program databases. Time to engraftment was measured as days from stem cell infusion until neutrophil engraftment, defined as the last of three consecutive days with an absolute neutrophil count (ANC) of 0.5 × 108/L or higher. As the primary outcome, time to engraftment was analyzed via a statistical &lt;em&gt;t&lt;/em&gt;-test. Patients with suspected ES were identified by both the administration of steroids beyond transplant Day 0 and through chart documentation of ES. Lastly, 1-year OS post-transplant was evaluated. Differences in time to engraftment, hospital LOS, rate of ES, OS, and cost were compared between groups with both descriptive and inferential statistics. Confounding factors, including clinically significant baseline characteristics, were analyzed through multivariate regression analysis.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;Between February 1, 2017, to October 24, 2022, 137 patients underwent melphalanbased auto-HSCT, with 129 patients included in the final analysis. At an average age of 62 years, the majority of patients were male, Caucasian, with multiple myeloma in CIBMTR stage of very good partial response (VGPR) and previous bortezomib, lenalidomide, and dexamethasone (VRd) induction therapy. Neutrophil engraftment was faster in the early administration group compared to delayed administration by approximately 1 day (95% CI -1.47 ̶ -0.79); &lt;em&gt;p&lt;/em&gt; &lt; 0.001). Median hospital LOS was also shorter with early G-CSF administration by 1 day (95% CI -3 ̶ -1, &lt;em&gt;p&lt;/em&gt; &lt; 0.001). There was no statistically significant difference between groups in ES occurrence or in OS at 1 year. Utilization of empiric antibiotics were similar, with shorter duration in the early administration group (difference 3.1 days). Finally, facility cost per patient transplant stay was lower with Day +1 G-CSF administration.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusion&lt;/h3&gt;&lt;div&gt;Day +1 G-CSF administration ha","PeriodicalId":37786,"journal":{"name":"Transplantation Reports","volume":"11 2","pages":"Article 100199"},"PeriodicalIF":0.0,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146175507","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Short telomere syndrome in lung transplantation: What do we know so far?","authors":"Kristina Akopyan ,&nbsp;Moustafa Younis ,&nbsp;Brandon Janssen ,&nbsp;Cynthia Gries ,&nbsp;Amir Emtiazjoo ,&nbsp;Mindaugas Rackauskas ,&nbsp;Biplab Saha","doi":"10.1016/j.tpr.2025.100193","DOIUrl":"10.1016/j.tpr.2025.100193","url":null,"abstract":"<div><div>Fibrotic lung disease is strongly linked to short telomere syndrome (STS). The database “PubMed” was used to retrieve articles related to both STS and lung transplantation using the term “short telomere lung transplant.” STS with lung transplantation is associated with greater risk of primary graft dysfunction (PGD), graft versus host disease (GVHD), infections including cytomegalovirus (CMV), development of accelerated liver cirrhosis, bone marrow failure, chronic lung allograft rejection (CLAD), and malignancy. However, data related to the impact of STS on lung transplant survival and changes in immunosuppression is currently insufficient, contradictory, and yet to be elucidated.</div></div>","PeriodicalId":37786,"journal":{"name":"Transplantation Reports","volume":"11 1","pages":"Article 100193"},"PeriodicalIF":0.0,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145792171","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rapid tumor lysis after immunosuppressive pause in post-transplant lymphoproliferative disorder","authors":"Joel Grunhut ,&nbsp;Ruchin B. Patel ,&nbsp;Silke V. Niederhaus ,&nbsp;Jonathan S. Bromberg ,&nbsp;Josue Alvarez-Casas ,&nbsp;Kathryn Kline ,&nbsp;Kapil K. Saharia ,&nbsp;Chandra S. Bhati","doi":"10.1016/j.tpr.2026.100195","DOIUrl":"10.1016/j.tpr.2026.100195","url":null,"abstract":"<div><h3>Objective</h3><div>Post-transplant lymphoproliferative disorder (PTLD) is a well-documented complication in patients undergoing solid organ transplantation, with varying clinical presentations and progression. Tumor lysis syndrome (TLS), although typically associated with hematologic malignancies, can occur in PTLD under rare circumstances, often triggered by cytotoxic therapies.</div></div><div><h3>Methods</h3><div>Here, we present a female in her late 50’s with a history of kidney transplantation complicated by PTLD who developed severe TLS following a temporary cessation of immunosuppressive therapy.</div></div><div><h3>Results</h3><div>Despite aggressive management, the patient deteriorated rapidly, culminating in respiratory failure, disseminated intravascular coagulation (DIC), and death.</div></div><div><h3>Conclusion</h3><div>This case highlights the unusual presentation, rapid progression, and catastrophic outcome of TLS in the context of PTLD without cytotoxic therapy, underlining the challenges in managing these patients. Early recognition and prompt management of TLS are crucial, especially in transplant recipients where clinical manifestations may be atypical.</div></div>","PeriodicalId":37786,"journal":{"name":"Transplantation Reports","volume":"11 1","pages":"Article 100195"},"PeriodicalIF":0.0,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145927334","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Serum bilirubin as a risk factor of chronic kidney disease in liver cirrhosis, not liver transplant patients","authors":"K.H. Mun","doi":"10.1016/j.tpr.2025.100192","DOIUrl":"10.1016/j.tpr.2025.100192","url":null,"abstract":"<div><h3>Background</h3><div>In liver cirrhosis patients with high serum bilirubin, serves as a marker of poor liver function and prognosis. However, bilirubin exhibits anti-inflammatory and antioxidant effects, resulting in protective role in renal function. The current study therefore, studied the relationship between high bilirubin levels and chronic kidney disease (CKD) in liver cirrhosis patients and compares it to liver transplant recipients to better understand bilirubin's role in these diseases.</div></div><div><h3>Methods</h3><div>Patients who with liver cirrhosis or liver transplant patients from 2018 to 2024 were recruited from single hospital. A total of 4064 patients with full data were studied. Patients were divided by serum bilirubin levels, and its association with CKD were studied in both liver cirrhosis and liver transplant patients.</div></div><div><h3>Results</h3><div>From each 3827 liver cirrhosis and 237 liver transplant patients, 940 (24.6 %) and 71 (30.0 %) patients were also diagnosed of CKD (total <em>n</em> = 1011). When divided by serum bilirubin levels, high serum bilirubin was associated with odds ratio (OR) of 1.97 (95 % confidence interval (CI) 1.67–2.31) in liver cirrhosis patients after adjustment. However, no association was observed in liver transplant patients with OR of 0.85 (95 % CI 0.41–1.77).</div></div><div><h3>Conclusions</h3><div>The current study has shown significant association between high bilirubin levels and increased CKD in liver cirrhosis patients but not in liver transplant patients.</div></div>","PeriodicalId":37786,"journal":{"name":"Transplantation Reports","volume":"11 1","pages":"Article 100192"},"PeriodicalIF":0.0,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145927332","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Feasibility and acceptance of electronic quality of life assessment in heart transplant recipients","authors":"Redouane Mahmoudi ,&nbsp;Legeai Camille ,&nbsp;Francis Guillemin ,&nbsp;Cécile Couchoud","doi":"10.1016/j.tpr.2025.100194","DOIUrl":"10.1016/j.tpr.2025.100194","url":null,"abstract":"<div><h3>Background</h3><div>Improved knowledge of the health-related quality of life (HRQoL) of heart transplant patients is needed. However, collecting such data is often challenging. As part of a larger project aiming to implement HRQoL tools for heart transplant patients in a national heart transplant registry, this study evaluated the feasibility and acceptability of collecting HRQoL via patient interviews and a pilot test of three questionnaire administration methods.</div></div><div><h3>Methods</h3><div>Fourteen heart transplant recipients were asked about their experience with completing questionnaires and their general knowledge about QoL tools. Transcriptions of these interviews were analyzed using deductive thematic analysis, a cohort of heart transplant recipients was assigned to one of three QoL questionnaire delivery methods: e-mail, tablet, or Quick Response (QR) code. Participants completed two HRQoL questionnaires (the Medical Outcomes Study 12-item Short Form and the Medication Experience Scale in Immunosuppressants) using the assigned method and provided feedback on these tools.</div></div><div><h3>Results</h3><div>Interviews revealed five key themes related to HRQoL questionnaires: experience using them, perceived usefulness and purpose, desired characteristics, preferred administration methods, and specific HRQoL domains to be assessed. All recipients agreed that the questionnaire should be brief and easy to complete.</div><div>In total, 34 heart transplant recipients agreed to participate, but only 19 patients (12 men) actually completed the study. Participants preferred completing the questionnaire in the hospital setting. Each of the three administration methods was considered acceptable by most respondents.</div></div><div><h3>Conclusions</h3><div>The choice of a QoL measurement tool to be implemented within a heart transplant registry must take into account patient opinions to ensure successful long-term data collection. Electronic tools do not appear to represent a major barrier for patients.</div></div>","PeriodicalId":37786,"journal":{"name":"Transplantation Reports","volume":"11 1","pages":"Article 100194"},"PeriodicalIF":0.0,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145792181","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Living donor liver transplantation for Wilson’s disease from a compound heterozygote donor with a low ceruloplasmin level: a case report","authors":"Hsin-Yen Chou ,&nbsp;Chia-Feng Yang ,&nbsp;Cheng-Yen Chen ,&nbsp;Hsin-Lin Tsai ,&nbsp;Hao-Jan Lei ,&nbsp;Yi-Fan Tsou ,&nbsp;Fang-Cheng Kuo ,&nbsp;Meng-Hsuan Chung ,&nbsp;Cheng-Yuan Hsia ,&nbsp;Shu-Cheng Chou ,&nbsp;Shen-Chih Wang ,&nbsp;Chin-Su Liu ,&nbsp;Niang-Cheng Lin","doi":"10.1016/j.tpr.2025.100190","DOIUrl":"10.1016/j.tpr.2025.100190","url":null,"abstract":"<div><div>Wilson’s disease (WD) is an autosomal recessive disorder resulting from mutations in the ATP7B gene. When chelation therapy proves ineffective, liver transplantation serves as the definitive treatment option. However, owing to the scarcity of cadaveric donor organs, living donor liver transplantation (LDLT) constitutes an important alternative. Nonetheless, the use of donors possessing compound heterozygous mutations in ATP7B and exhibiting low ceruloplasmin levels remains a subject of controversy.</div><div>We report a 49-year-old woman with Wilson's disease (WD) who presented with liver cirrhosis, bleeding esophageal varices, and hepatocellular carcinoma. She underwent living donor liver transplantation (LDLT) from her 18-year-old son, who carried compound heterozygous mutations in the ATP7B gene and exhibited low ceruloplasmin and copper levels. Both the donor and recipient recovered well. The recipient’s liver function and copper metabolism normalized without the need for further chelation therapy.</div><div>This case indicates that individuals who are compound heterozygous carriers of ATP7B with low ceruloplasmin levels may be considered suitable donors following a comprehensive assessment. A multidisciplinary approach is crucial to the donor selection process in Wilson's disease (WD).</div></div>","PeriodicalId":37786,"journal":{"name":"Transplantation Reports","volume":"11 1","pages":"Article 100190"},"PeriodicalIF":0.0,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145765912","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}